Oxygen Use Cohort vs No Oxygen Use Cohort: Number of Participants With Disease Progression From Index Date to Follow-up Forced Vital Capacity (FVC) Result
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0233 | 0.0215 | 0.0253 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0185 | 0.0169 | 0.0202 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00482 | 0.0023 | 0.00735 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.26 | 1.12 | 1.42 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.27 | 1.12 | 1.43 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Oxygen Use Cohort than on No Oxygen Use Cohort | 207 | 136 | 435 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Oxygen Use Cohort | Interstitial lung disease (ILD) patients with ≥1 medical claim for oxygen therapy after fibrosing ILD diagnosis. | 575 | 24,680 | OG000 | ClinicalTrials.gov |
| Group 2 | No Oxygen Use Cohort | Patients who were matched to a patient in the oxygen therapy cohort. | 456 | 24,680 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Number of Participants With Disease Progression From Index Date to Follow-up Forced Vital Capacity (FVC) Result | ClinicalTrials.gov |
| Description | The Number of participants with disease progression is reported instead of time to disease progression in the Outcome Measure Data Table.~Disease progression was defined as a 10% relative change between the index date to follow-up FVC result. | ClinicalTrials.gov |
| Time frame | Up to month 12 of follow-up, in patient identification period from 01 October 2016 through 30 June 2022. | ClinicalTrials.gov |
| Population | Among the 24,686 fibrosing Interstitial Lung Disease (ILD) patients who initiated oxygen therapy during the Aim 1 follow-up period, 24,680 were successfully matched at a 1:1 ratio with a fibrosing ILD patient who did not yet initiate oxygen therapy.~Patients of the matched cohort are included for which pre-index and follow-up forced vital capacity (FVC) results were available. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease | ClinicalTrials.gov |
| NCT number | NCT05957198 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Lung Diseases, Interstitial | ClinicalTrials.gov |
| Interventions | ClinicalTrials.gov | |
| Lead sponsor | Boehringer Ingelheim | ClinicalTrials.gov |
| Results first posted | 2024-11-21 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT05957198?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.